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BACKGROUND: It is not clear how the pathology, presentation and outcome for patients who present with de novo metastatic
breast cancer (dnMBC) compare with those who later develop distant metastases. DnMBC is uncommon in younger patients. We
describe these differences within a cohort of young patients in the United Kingdom.
METHODS: Women aged 40 years or younger with a first invasive breast cancer were recruited to the prospective POSH national
cohort study. Baseline clinicopathological data were collected, with annual follow-up. Overall survival (OS) and post-distant relapse-
free survival (PDRS) were assessed using Kaplan–Meier curves.
RESULTS: In total, 862 patients were diagnosed with metastatic disease. DnMBC prevalence was 2.6% (76/2977). Of those with
initially localised disease, 27.1% (786/2901) subsequently developed a distant recurrence. Median follow-up was 11.00 years (95% CI
10.79–11.59). Patients who developed metastatic disease within 12 months had worse OS than dnMBC patients (HR 2.64; 1.84–3.77).
For PDRS, dnMBC was better than all groups, including those who relapsed after 5 years. Of dnMBC patients, 1.3% had a gBRCA1,
and 11.8% a gBRCA2 mutation.
CONCLUSIONS: Young women with dnMBC have better PDRS than those who develop relapsed metastatic breast cancer. A
gBRCA2 mutation was overrepresented in dnMBC.
British Journal of Cancer (2020) 122:1618–1629; https://doi.org/10.1038/s41416-020-0784-z
BACKGROUND
Breast cancer is the most common neoplasm in women, with over
55,000 new diagnoses per year in the United Kingdom.1 The vast
majority of patients present with disease localised to the breast
and axillary lymph nodes, and are treated with the aim of cure, but
for the 6–7% who present with de novo metastatic disease
(dnMBC), treatment is usually with palliative intent.1,2 Overall, the
median survival of those with metastatic breast cancer (MBC) is
2–3 years,3 although the range is wide, with some patients with
ER+ or HER2+ disease living much longer. Most MBC survival
analyses are retrospective, with a median age of 53–65 (with
<15% of participants being aged under 40).4–6
A number of studies to date have shown a longer survival time
following diagnosis of metastases for those presenting with
dnMBC, compared with those who later develop distant
metastases after initial treatment for early breast cancer (recurrent
MBC, rMBC).5,7–9 In a retrospective multicentre study evaluating
815 consecutive patients with MBC in the Netherlands from 2007
to 2009, this was only true for rMBC patients with a metastasis-free
interval (MFI) of <24 months.6
The phenotype of breast cancer for those with dnMBC is
unclear. Compared with rMBC cases, more favourable pathological
features have been reported, such as a lower frequency of triple-
negative carcinomas.5,7 However, more aggressive features have
also been documented, such as larger tumours, and an increased
frequency that is Grade 3.5 However, with median follow-up
length of less than 5 years, interpretation of these studies is
limited by the omission of late ER+ ve recurrences.
Data regarding clinical presentation have also yielded varying
results. A higher prevalence of bone involvement in the dnMBC
group at diagnosis has been reported in two studies: one reported
an equal prevalence of brain metastases, and the other reported
fewer brain metastases compared with those with rMBC.6,7
Another study also found a lower prevalence of brain metastases,
but a similar prevalence of bone involvement.5 Locoregional
management in patients with dnMBC is the subject of ongoing
debate, as results from retrospective studies have been con-
founded by selection bias, and the results from randomised trials
have been conflicting.10
Published studies on dnMBC have been limited by their
retrospective nature (with the risk of survival bias), or by small
patient numbers and short follow-up periods. None of them has
complete germline BRCA status, or evaluated a specific age group.
The incidence of breast cancer in young women (aged <40) is low,
but increasing.11 Young women are more likely to have breast
cancer with adverse biological features, including higher grade,
absence of hormone receptors, lymph node involvement and
vascular invasion.12 Young age has been consistently shown to be
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an adverse prognostic factor, with a higher risk of distant
recurrence.11 In addition, this group is less likely to have co-
morbidities; they may tolerate chemotherapy and other treat-
ments better than older patients. Although young women present
more frequently with stage III disease, dnMBC is found infre-
quently (1% of those aged under 40 in one retrospective study).13
The POSH study, a prospective observational study of almost 3000
patients aged 40 years or younger with a first diagnosis of invasive
breast cancer,12 provides a unique opportunity to study the
natural history of dnMBC in young women. Patients were recruited
between 2000 and 2008 in the United Kingdom. A wealth of
clinicopathological data is available for these patients, including
body mass index and ethnicity, and genotyping for germline BRCA
mutation status has been performed on the vast majority (> 94%).
This is an important variable to study as BRCA mutation status is
increasingly being incorporated in decision-making regarding
optimal treatment.11 We aimed to characterise the clinical
features, pattern of disease progression and survival of young
breast cancer patients who present with metastatic disease,
compared with those who later develop distant metastases, in a
large prospective cohort genotyped for germline BRCA1/2.
METHODS
Prospective outcomes in sporadic vs. hereditary breast cancer
(POSH) are a multicentre prospective observational cohort study
of young women diagnosed with breast cancer in the United
Kingdom. The detailed study protocol was published in 2007.14
The study received approval from the South West Multi-Centre
Research Ethics Committee (MREC 00/6/69). Written informed
consent was obtained from all participants.
Patients
In total, 3021 female patients were recruited from 127 UK
hospitals. Patients were eligible if they were diagnosed with an
invasive breast cancer between January 1, 2000 and January 31,
2008, at an age of 40 years or younger. Patients were excluded if
they had a previous invasive malignancy (excluding non-
melanomatous skin cancer), Patients were consented within
12 months of initial diagnosis. All patients received treatment
according to local protocols. Patients with confirmed distant
metastatic disease at diagnosis (stage M1) according to the local
site comprised the dnMBC cohort. Patients who initially had
localised disease (stage M0), but developed distant metastatic
disease within the follow-up period, (according to site reporting)
comprised the rMBC cohort. Tissue diagnosis of metastatic disease
was not mandated by the study. Patients without metastatic
disease at any time were not included in this analysis.
Data collection
Information regarding personal characteristics, tumour pathology,
stage and treatment received was collected from medical records
at study entry. Family history was collected by questionnaire.
Pathology and imaging data were verified with copies of original
reports. Follow-up data, including date and site of disease
recurrence, were obtained from medical records at 6, 12 months
and thereafter annually until death or loss to follow-up. Follow-up
interval was determined according to local standards; no imaging
or other investigation was mandated by this study, as it was
observational. Patients were flagged in the National Health Service
Medical Research Information Service to facilitate automatic
notification of the date and cause of death. This study presents
analyses conducted on follow-up data received until 26 June 2016.
Biological testing
Oestrogen receptor (ER), progesterone receptor (PR) and HER2
receptor status of primary tumours were determined from routine
diagnostic pathology reports. Hormone receptor concentrations
equivalent to an Allred score of 3 or more were categorised as
positive. Tissue microarray (TMA) immunohistochemical staining
was used to supplement missing information regarding receptor
status.
DNA for genotyping was extracted from whole-blood samples
collected at recruitment. A multiplex amplicon-based library
preparation system, Fluidigm Access Array (Fluidigm UK, Cam-
bridge, UK) was used to sequence a panel of breast cancer
susceptibility genes, including BRCA1/2 and TP53. Illumina
HiSeq2500 next-generation sequencing platform was utilised
(Illumina, Little Chesterford, UK). If patients met current UK
guidelines for genetic testing, multiplex ligation probe analysis
was used to ensure that mutations consisting of large exonic
deletions or duplications were not missed. Pathogenic variants
were confirmed by Sanger sequencing. Those with variants of
unknown significance were classified as BRCA-negative.
Statistical methods
Statistical analyses were performed according to a pre-specified
statistical analysis plan (Supplementary Information) as per
STROBE guidelines.
The primary objective was the comparison of overall survival
(OS) of patients with dnMBC with that of patients with rMBC with
a MFI of less than 12 months (early12). OS was defined as the time
from the date of diagnosis to death from any cause. MFI was
defined as the time from the date of diagnosis to the date of the
first distant relapse.
The secondary objectives included the comparison of OS and
post-distant relapse survival (PDRS) of patients with dnMBC with
that of patients with rMBC with a MFI of less than 24 months
(early24). PDRS was defined as time from the date of diagnosis of
the first distant metastases (date of diagnosis of primary tumour
for patients with dnMBC) to death from any cause. Other
secondary objectives included the comparison of PDRS of patients
with dnMBC vs. early-12 patients, and the description of
clinicopathological features in patients with dnMBC and those
with rMBC in four cohorts (recurrent disease within 12 months,
within 24 months, between 24 and 60 months and after
60 months). Patient and tumour characteristics included ethnicity,
body mass index (BMI), germline BRCA status, first site of
metastasis and primary tumour grading/receptor status. Time-to-
event outcomes were described using Kaplan–Meier curves, and
analysed using Cox regression models; stratified Cox models or
flexible parametric survival models were used in cases where
hazards were time-varying. All multivariable analyses were
adjusted for age at diagnosis, BMI, grade, tumour size, patholo-
gical N stage, ethnicity and ER and HER2 tumour status. Further
objectives included the comparison of OS of dnMBC patients who
had surgery (breast-conserving surgery, nodal surgery only or
mastectomy) vs. those who had no surgery and assessment of
correlation between MFI and PDRS in rMBC patients using the
survcorr command in R. Statistical analyses were carried out using
Stata v15.1 and RStudio v1.1.456.
The study size and power calculations are discussed in the study
protocol.12
RESULTS
A total of 3021 eligible women were recruited to the POSH
study. For this study, 44 women were excluded (42 were aged
41–50 years and 2 had missing primary tumour data). Of the
2977 women included, 862 (29.0%) were diagnosed with
metastatic disease and comprise the analysis population. There
were 76 women (2.6%) who presented with dnMBC. As of June
2016, the distant recurrence rate amongst the 2901 women with
localised disease at presentation is 27.1% (n= 786). Median
follow-up of the analysis population was 11.00 years (95% CI
10.79–11.59, n= 862).
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Of patients with rMBC, 70 (8.9%) developed metastases within
12 months of diagnosis (early 12). There were 268 women (34.1%),
who developed metastatic disease within 24 months of their first
diagnosis (early 24), 360 (45.8%) within 24–60 months (early
24–60) and 158 (20.1%) after 60 months (late).
Baseline clinicopathological data
For the 862 women diagnosed with metastatic disease, clinico-
pathological data can be seen in Table 1. The proportion of
patients that were very young (aged 30 or less) decreased with
time to relapse amongst rMBC patients (18.6% for early 12, 6.3%
for late relapse). The largest proportion of BRCA1 mutation carriers
was found in the early-24 group (8.6%; 23/268). The largest
proportion of BRCA2 mutation carriers was found in the dnMBC
group (11.8%; 9/76); there was only one BRCA1 mutation in this
group (1.3%; 1/76).
On review of tumour characteristics, ER positivity was positively
correlated with later time of relapse: 45.3% of early 24, 72.4% of
early 24–60 and 84.2% of late-relapse cases (69.3% of dnMBC).
HER2 positivity was the highest in the dnMBC cohort with 47.9%
vs. 32.4% in the early-24 group, and 24.3% in the late-relapse
group. The median maximum tumour size was the largest in the
dnMBC group at 35 mm, compared with 25mm in the late-relapse
group. The proportion of cases with Grade 3 disease was inversely
proportional with time to relapse amongst the rMBC group: 87.0%
of early 12 and 47.4% of the late-relapse group (63.2% of dnMBC).
The early-12 group had a high proportion of adverse tumour
characteristics, including Grade 3 disease (87.0%), LVI (76.9%) and
node positivity (83.8%). The number of involved lymph nodes was
more than 10 in a quarter of cases (25.0%), and over a third of
cases were triple negative (34.3%).
Survival
Patients who relapsed within 12 months had a significantly worse
OS than the dnMBC group (Fig. 1a), with a HR for death of 2.64
(1.84–3.77; p= < 0.001). For those who relapsed after 24 months,
the OS varied over time, consistent with the delay from diagnosis
to metastatic disease (clearly the HR for death at 2 years was very
small). However, results from the time-varying regression model
show that by 5 years, the risk of death for those who relapsed
between 24 and 60 months was increased, compared with the
dnMBC group, with a 5-year HR of 1.55 (1.10–2.18, p= 0.013) and
10-year HR 2.21 (1.02–4.77, p= 0.044) (Fig. 1b; Supplementary
S1A). Similarly, the time-varying regression model shows that, for
those who relapsed after 60 months, the risk of death at 5 years
was very small, but compared with the dnMBC group, the 10-year
HR was 1.74 (0.80–3.78, p= 0.160) (Fig. 1b; Supplementary S1B).
There was longer PDRS for dnMBC compared with all other groups
who developed metastases, including those with late relapse after
60 months (HR 2.67; 1.92–3.71, p < 0.001) (Fig. 2a, b). The hazard
ratio for PDRS for early 12, compared with dnMBC, decreased over
time (Fig. 2c).
We assessed for a correlation between time from initial
diagnosis to metastatic relapse (metastasis-free interval, MFI)
and PDRS, and found a very slight positive Rho correlation
coefficient of 0.045 (95% CI: −0.023 to 0.113), suggesting that
there is not a close correlation between these two factors.
A multivariable analysis was performed to assess for factors
related to duration of survival in those with dnMBC vs. early12. For
OS (Table 2), early-12 patients maintained a significantly worse OS
compared with dnMBC after adjustment for other factors (HR 3.76;
2.22–6.38; p < 0.001). Positive nodes were found to be associated
with significantly shorter survival (HR 2.29; 1.17–4.47; p= 0.015),
whilst patients with HER2-positive tumours were at reduced risk of
death (HR 0.500; 0.311–0.802; p= 0.004). Similar results were also
found in the multivariable analyses for PDRS.
For early-24 patients (Table 3), PDRS was worse compared with
dnMBC patients after adjustment for other factors at 2 and 5 years
(HR 2.53; 1.50–4.27; p < 0.001, and HR 2.42; 1.39–4.22; p= 0.0019).
Again, positive nodes were found to be a significant risk of earlier
distant relapse (HR 1.42; 1.05–1.93; p= 0.024), whilst patients with
HER2-positive tumours had longer survival (HR 0.66; 0.51–0.86;
p= 0.002). ER-positive status was protective for disease relapse at
2 years compared with ER-negative (HR 0.50; 0.38–0.67; p < 0.001),
but not at 5 or 10 years.
Sites of metastases
Regarding sites of metastases (at any time during disease course),
patients in the dnMBC and early-12 groups were most likely to
have widespread (bone, visceral and brain) disease, with 26.3%
and 21.4%, respectively, compared with 13.6% in the late-relapse
group. Patients with dnMBC had the highest prevalence of brain
metastases (39.5%), which decreased with time to relapse (24.3%
in the late-relapse group). The proportion with bone metastases
correlated with time to relapse amongst those with rMBC: 54.3%
of the early 12, up to 71.4% with late relapse (71.1% of the dnMBC
group). Visceral metastases were equally prevalent throughout all
groups.
When the first site of metastases was evaluated, bone-only or
nodal-only disease at presentation was most common in the
dnMBC group (30.3% and 15.8%, respectively). Visceral metastases
at presentation of metastatic disease were less common in the
dnMBC group (52.6%), and most common in the early 24–60
group (66.8%). Bony metastases at presentation were present in
50% of the early-12 group, increasing to 60.4% of the late- relapse
group (57% of dnMBC). Brain metastases at presentation
decreased with time to relapse amongst the rMBC cohort: 18.6%
of early 12 and 8.7% of late relapses (1.3% of dnMBC).
Treatment
Amongst dnMBC patients, 65.8% (50/76) had local surgery.
Survival was better in those who had surgery, with a univariable
HR of 0.41 (0.24–0.68, p= <0.001) and 5-year OS of 44.6%
(42.24–46.94) vs. 15.27% (7.85–24.97) (Fig. 3). Patients were treated
with palliative cytotoxic chemotherapy in 98.7% of the dnMBC
group vs. 71.4% in the early-12 group, and 70.3% in the late-
relapse group. Palliative hormone therapy was also the highest in
the dnMBC group (68.4%), whereas it was given in 28.6% of
patients who relapsed within 12 months and 61.4% of patients
with a late relapse. Palliative radiotherapy was also administered
at the highest rate in the dnMBC group, with 76.3% of patients
receiving it, compared with 60.0% in the early-12 group and 50.0%
in the late-relapse group.
DISCUSSION
This is the largest prospective study to evaluate metastatic disease
in the young-onset breast cancer population. We have shown that
young women who develop secondary metastatic disease, even if
greater than 5 years after diagnosis, have shorter survival time
following diagnosis of metastases, compared with those who
present with de novo metastatic disease. When survival from
initial diagnosis (OS) was compared, this was superior for those
with dnMBC, compared with those who developed relapsed
disease within 24 months.
In this study, nearly a third (27.1%) of women developed
metastatic recurrence after presenting with localised disease. Only
2.6% of this cohort had metastatic disease at presentation, lower
than the national (unselected age) estimate of 6–7% from Cancer
Research UK.1 Late stage at diagnosis is reported to be more
common in women aged greater than 80, and so this likely
contributes to the higher figure nationally.1,13 It is also possible
that there was an element of selection bias, as oncologists may
have chosen to recruit patients with metastatic disease to an
interventional study rather than an observational one (although
participation in an interventional study did not exclude patients
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Table 1. Demographic table by M-stage categories.
M1 (dnMBC)
(n= 76)
M0 < 12 months
(n= 70)








Age at diagnosis (years)
18–25 4 (5.3%) 0 4 (1.5%) 6 (1.7%) 2 (1.3%) 16 (1.9%)
26–30 6 (7.9%) 13 (18.6%) 37 (13.8%) 37 (10.3%) 8 (5.1%) 88 (10.2%)
31–35 27 (35.5%) 26 (37.1%) 95 (35.4%) 117 (32.5%) 53 (33.5%) 292 (33.9%)
36–40 39 (51.3%) 31 (44.3%) 132 (49.3%) 200 (55.6%) 95 (60.1%) 466 (54.1%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Ethnicity
Caucasian 67 (88.2%) 60 (85.7%) 236 (89.7%) 328 (91.6%) 136 (86.6%) 767 (89.8%)
Black 6 (7.9%) 7 (10.0%) 17 (6.5%) 18 (5.0%) 13 (8.3%) 54 (6.3%)
Asian 3 (3.9%) 3 (4.3%) 8 (3.0%) 10 (2.8%) 7 (4.5%) 28 (3.3%)
Other 0 0 2 (0.8%) 2 (0.6%) 1 (0.6%) 5 (0.6%)
Total 76 (100%) 70 (100%) 263 (100%) 358 (100%) 157 (100%) 854 (100%)
Missing 0 0 5 (1.9%) 2 (0.6%) 1 (0.6%) 8 (0.9%)
BMI, categorical
Underweight 32 (45.1%) 30 (44.8%) 119 (45.4%) 167 (47.2%) 80 (51.3%) 398 (47.2%)
Overweight 21 (29.6%) 21 (31.3%) 85 (32.4%) 105 (29.7%) 38 (24.4%) 249 (29.5%)
Obese 18 (25.4%) 16 (23.9%) 58 (22.1%) 82 (23.2%) 38 (24.4%) 196 (23.3%)
Total 71 (100%) 67 (100%) 262 (100%) 354 (100%) 156 (100%) 843 (100%)
Missing 5 (6.6%) 3 (4.3%) 6 (2.2%) 6 (1.7%) 2 (1.3%) 19 (2.2%)
Family history
No 48 (68.6%) 45 (67.2%) 180 (68.7%) 238 (68.0%) 106 (68.8%) 572 (68.4%)
Yes 22 (31.4%) 22 (32.8%) 82 (31.3%) 112 (32.0%) 48 (31.2%) 264 (31.6%)
Total 70 (100%) 67 (100%) 262 (100%) 350 (100%) 154 (100%) 836 (100%)
Missing 6 (7.9%) 3 (4.3%) 6 (2.2%) 10 (2.8%) 4 (2.5%) 26 (3.0%)
Presentation
Symptomatic 76 (100.0%) 70 (100.0%) 264 (99.2%) 360 (100.0%) 155 (98.1%) 855 (99.4%)
Screen-detected 0 0 2 (0.8%) 0 1 (0.6%) 3 (0.3%)
Other 0 0 0 0 2 (1.3%) 2 (0.2%)
Total 76 (100%) 70 (100%) 266 (100%) 360 (100%) 158 (100%) 860 (100%)
Missing 0 0 2 (0.7%) 0 0 2 (0.2%)
BRCA (BRCA1 or 2) status
BRCA− 66 (86.8%) 62 (88.6%) 237 (88.4%) 325 (90.3%) 138 (87.3%) 766 (88.9%)
BRCA+ 10 (13.2%) 8 (11.4%) 31 (11.6%) 35 (9.7%) 20 (12.7%) 96 (11.1%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
BRCA1 status
BRCA1− 75 (98.7%) 66 (94.3%) 245 (91.4%) 346 (96.1%) 148 (93.7%) 814 (94.4%)
BRCA1+ 1 (1.3%) 4 (5.7%) 23 (8.6%) 14 (3.9%) 10 (6.3%) 48 (5.6%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
BRCA2 status
BRCA2− 67 (88.2%) 66 (94.3%) 260 (97.0%) 339 (94.2%) 148 (93.7%) 814 (94.4%)
BRCA2+ 9 (11.8%) 4 (5.7%) 8 (3.0%) 21 (5.8%) 10 (6.3%) 48 (5.6%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
TP53 status
TP53– 76 (100.0%) 69 (98.6%) 267 (99.6%) 359 (99.7%) 158 (100.0%) 860 (99.8%)
TP53+ 0 1 (1.4%) 1 (0.4%) 1 (0.3%) 0 2 (0.2%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Histological grade
1 2 (2.9%) 0 1 (0.4%) 10 (2.8%) 6 (3.9%) 19 (2.3%)
2 23 (33.8%) 9 (13.0%) 42 (16.0%) 123 (35.0%) 74 (48.7%) 262 (31.4%)
3 43 (63.2%) 60 (87.0%) 220 (83.7%) 218 (62.1%) 72 (47.4%) 553 (66.3%)
Total 68 (100%) 69 (100%) 263 (100%) 351 (100%) 152 (100%) 834 (100%)
Missing 8 (10.5%) 1 (1.4%) 5 (1.9%) 9 (2.5%) 6 (3.8%) 28 (3.2%)
Histological type
Ductal 65 (86.7%) 68 (97.1%) 239 (89.8%) 308 (86.8%) 136 (87.2%) 748 (87.8%)
Ductal and lobular 4 (5.3%) 2 (2.9%) 7 (2.6%) 12 (3.4%) 4 (2.6%) 27 (3.2%)
Lobular 3 (4.0%) 0 6 (2.3%) 21 (5.9%) 14 (9.0%) 44 (5.2%)
Medullary 0 0 2 (0.8%) 2 (0.6%) 0 4 (0.5%)
Survival and disease characteristics of de novo versus recurrent. . .





M0 < 12 months
(n= 70)








Metaplastic 0 0 4 (1.5%) 0 0 4 (0.5%)
Mixed 2 (2.7%) 0 4 (1.5%) 4 (1.1%) 0 10 (1.2%)
Other 1 (1.3%) 0 4 (1.5%) 8 (2.3%) 2 (1.3%) 15 (1.8%)
Total 75 (100%) 70 (100%) 266 (100%) 355 (100%) 156 (100%) 852 (100%)
Missing 1 (1.3%) 0 2 (0.7%) 5 (1.4%) 2 (1.3%) 10 (1.2%)
Surgical margins (mm)
0 5 (12.2%) 6 (10.0%) 27 (11.9%) 33 (12.0%) 15 (11.7%) 80 (11.9%)
>0 to <1 0 3 (5.0%) 7 (3.1%) 3 (1.1%) 3 (2.3%) 13 (1.9%)
>=1 to <=5 19 (46.3%) 36 (60.0%) 115 (50.9%) 155 (56.4%) 66 (51.6%) 355 (53.0%)
>5 17 (41.5%) 15 (25.0%) 77 (34.1%) 84 (30.5%) 44 (34.4%) 222 (33.1%)
Total 41 (100%) 60 (100%) 226 (100%) 275 (100%) 128 (100%) 670 (100%)
Missing 35 (46.1%) 10 (14.3%) 42 (15.7%) 85 (23.6%) 30 (19.0%) 192 (22.3%)
Lymphovascular invasion
Absent 18 (31.0%) 15 (23.1%) 68 (27.4%) 121 (35.6%) 60 (41.1%) 267 (33.7%)
Present 40 (69.0%) 50 (76.9%) 180 (72.6%) 219 (64.4%) 86 (58.9%) 525 (66.3%)
Total 58 (100%) 65 (100%) 248 (100%) 340 (100%) 146 (100%) 792 (100%)
Missing 18 (23.7%) 5 (7.1%) 20 (7.5%) 20 (5.6%) 12 (7.6%) 70 (8.1%)
Path T stage
T0 1 (2.1%) 1 (1.5%) 7 (2.7%) 7 (2.0%) 3 (1.9%) 18 (2.2%)
T1 16 (33.3%) 16 (23.9%) 79 (30.6%) 136 (38.7%) 68 (43.9%) 299 (36.8%)
T2 22 (45.8%) 34 (50.7%) 128 (49.6%) 168 (47.9%) 70 (45.2%) 388 (47.8%)
T3 9 (18.8%) 14 (20.9%) 41 (15.9%) 38 (10.8%) 14 (9.0%) 102 (12.6%)
T4 0 2 (3.0%) 3 (1.2%) 2 (0.6%) 0 5 (0.6%)
Total 48 (100%) 67 (100%) 258 (100%) 351 (100%) 155 (100%) 812 (100%)
Missing 28 (36.8%) 3 (4.3%) 10 (3.7%) 9 (2.5%) 3 (1.9%) 50 (5.8%)
Max tumour size (invasive) (mm)
Median 35 32 30 27 25 28
Range 2–80 3–160 2–160 0–199 .5–102 0–199
IQRa 18–49 25–60 20–47 18–41 18–40 19–43
Missing 29 (38.2%) 5 (7.1%) 18 (6.7%) 21 (5.8%) 6 (3.8%) 74 (8.6%)
No. of positive lymph nodes
0 11 (23.4%) 11 (16.2%) 66 (25.5%) 96 (26.8%) 49 (31.4%) 222 (27.1%)
1–3 12 (25.5%) 21 (30.9%) 89 (34.4%) 128 (35.8%) 70 (44.9%) 299 (36.5%)
4–9 11 (23.4%) 19 (27.9%) 52 (20.1%) 86 (24.0%) 30 (19.2%) 179 (21.8%)
10+ 13 (27.7%) 17 (25.0%) 52 (20.1%) 48 (13.4%) 7 (4.5%) 120 (14.6%)
Total 47 (100%) 68 (100%) 259 (100%) 358 (100%) 156 (100%) 820 (100%)
Missing 29 (38.2%) 2 (2.9%) 9 (3.4%) 2 (0.6%) 2 (1.3%) 42 (4.9%)
ER status
Negative 23 (30.7%) 41 (58.6%) 146 (54.7%) 99 (27.6%) 25 (15.8%) 293 (34.1%)
Positive 52 (69.3%) 29 (41.4%) 121 (45.3%) 260 (72.4%) 133 (84.2%) 566 (65.9%)
Total 75 (100%) 70 (100%) 267 (100%) 359 (100%) 158 (100%) 859 (100%)
Missing 1 (1.3%) 0 1 (0.4%) 1 (0.3%) 0 3 (0.3%)
PR status
Negative 24 (40.7%) 41 (66.1%) 161 (70.6%) 122 (41.9%) 27 (21.8%) 334 (47.6%)
Positive 35 (59.3%) 21 (33.9%) 67 (29.4%) 169 (58.1%) 97 (78.2%) 368 (52.4%)
Total 59 (100%) 62 (100%) 228 (100%) 291 (100%) 124 (100%) 702 (100%)
Missing 17 (22.4%) 8 (11.4%) 40 (14.9%) 69 (19.2%) 34 (21.5%) 160 (18.6%)
HER2 status
Negative 38 (52.1%) 44 (62.9%) 177 (67.6%) 224 (66.3%) 106 (75.7%) 545 (67.0%)
Positive 35 (47.9%) 26 (37.1%) 85 (32.4%) 114 (33.7%) 34 (24.3%) 268 (33.0%)
Total 73 (100%) 70 (100%) 262 (100%) 338 (100%) 140 (100%) 813 (100%)
Missing 3 (3.9%) 0 6 (2.2%) 22 (6.1%) 18 (11.4%) 49 (5.7%)
TNBC statusb
Not TNBC 72 (94.7%) 46 (65.7%) 168 (62.7%) 305 (84.7%) 143 (90.5%) 688 (79.8%)
TNBC 4 (5.3%) 24 (34.3%) 100 (37.3%) 55 (15.3%) 15 (9.5%) 174 (20.2%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Missing 0 0 0 0 0 0
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Localised 30 (61.2%) 40 (63.5%) 161 (66.5%) 202 (61.6%) 89 (64.5%) 482 (63.7%)
Multifocal 19 (38.8%) 23 (36.5%) 81 (33.5%) 126 (38.4%) 49 (35.5%) 275 (36.3%)
Total 49 (100%) 63 (100%) 242 (100%) 328 (100%) 138 (100%) 757 (100%)
Missing 27 (35.5%) 7 (10.0%) 26 (9.7%) 32 (8.9%) 20 (12.7%) 105 (12.2%)
Surgical type
BCS 16 (21.1%) 18 (25.7%) 97 (36.2%) 120 (33.3%) 59 (37.3%) 292 (33.9%)
Mastectomy 33 (43.4%) 50 (71.4%) 166 (61.9%) 238 (66.1%) 98 (62.0%) 535 (62.1%)
Nodal surgery only 1 (1.3%) 0 0 1 (0.3%) 0 2 (0.2%)
None 26 (34.2%) 2 (2.9%) 5 (1.9%) 1 (0.3%) 1 (0.6%) 33 (3.8%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Neoadjuvant chemotherapyc
Yes 0 28 (40.0%) 87 (32.5%) 84 (23.3%) 26 (16.5%) 197 (22.9%)
No 76 (100%) 42 (60%) 181 (67.5%) 276 (76.7%) 132 (83.5%) 665 (77.1%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Adjuvant chemotherapy
Yes 0 40 (57.1%) 173 (64.6%) 256 (71.1%) 120 (75.9%) 549 (63.7%)
No 76 (100%) 30 (42.9%) 95 (35.4%) 104 (28.9%) 38 (24.1%) 313 (36.3%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Palliative chemotherapy
Yes 75 (98.7%) 50 (71.4%) 204 (76.1%) 301 (83.6%) 111 (70.3%) 691 (80.2%)
No 1 (1.3%) 20 (28.6%) 64 (23.9%) 59 (16.4%) 47 (29.7%) 171 (19.8%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Palliative trastuzumab
Yes 12 (15.8%) 6 (8.6%) 19 (7.1%) 36 (10.0%) 10 (6.3%) 77 (8.9%)
No 64 (84.2%) 64 (91.4%) 249 (92.9%) 324 (90.0%) 148 (93.7%) 785 (91.1%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Palliative radiotherapy
Yes 58 (76.3%) 42 (60.0%) 155 (57.8%) 205 (56.9%) 79 (50.0%) 497 (57.7%)
No 18 (23.7%) 28 (40.0%) 113 (42.2%) 155 (43.1%) 79 (50.0%) 365 (42.3%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Hormone treatment
Yes 52 (68.4%) 20 (28.6%) 80 (29.9%) 169 (46.9%) 97 (61.4%) 398 (46.2%)
No 24 (31.6%) 50 (71.4%) 188 (70.1%) 191 (53.1%) 61 (38.6%) 464 (53.8%)
Total 76 (100%) 70 (100%) 268 (100%) 360 (100%) 158 (100%) 862 (100%)
Site of metastases at any time
Bone 8 (10.5%) 7 (10.0%) 31 (12.0%) 31 (8.9%) 14 (10.0%) 84 (10.2%)
Bone–Brain 4 (5.3%) 4 (5.7%) 7 (2.7%) 13 (3.7%) 2 (1.4%) 26 (3.2%)
Bone–Viscd 22 (28.9%) 12 (17.1%) 84 (32.4%) 128 (36.8%) 65 (46.4%) 299 (36.3%)
Bone–Visc–Brain 20 (26.3%) 15 (21.4%) 41 (15.8%) 68 (19.5%) 19 (13.6%) 148 (18.0%)
Brain 3 (3.9%) 4 (5.7%) 18 (6.9%) 11 (3.2%) 5 (3.6%) 37 (4.5%)
Nodal 4 (5.3%) 3 (4.3%) 8 (3.1%) 15 (4.3%) 10 (7.1%) 37 (4.5%)
Visc 12 (15.8%) 21 (30.0%) 53 (20.5%) 55 (15.8%) 17 (12.1%) 137 (16.6%)
Visc–Brain 3 (3.9%) 4 (5.7%) 17 (6.6%) 27 (7.8%) 8 (5.7%) 55 (6.7%)
Total 76 (100%) 70 (100%) 259 (100%) 348 (100%) 140 (100%) 823 (100%)
Missing 0 0 9 (3.4%) 12 (3.3%) 18 (11.4%) 39 (4.5%)
Site of first metastases
Bone 23 (30.3%) 16 (22.9%) 52 (20.1%) 73 (21.1%) 30 (21.7%) 178 (21.7%)
Bone–Brain 0 2 (2.9%) 4 (1.5%) 6 (1.7%) 0 10 (1.2%)
Bone–Visc 20 (26.3%) 12 (17.1%) 73 (28.2%) 108 (31.2%) 58 (42.0%) 259 (31.6%)
Bone–Visc–Brain 0 5 (7.1%) 13 (5.0%) 22 (6.4%) 2 (1.4%) 37 (4.5%)
Brain 1 (1.3%) 4 (5.7%) 18 (6.9%) 13 (3.8%) 5 (3.6%) 37 (4.5%)
Nodal 12 (15.8%) 4 (5.7%) 17 (6.6%) 23 (6.6%) 15 (10.9%) 67 (8.2%)
Visc 20 (26.3%) 25 (35.7%) 73 (28.2%) 88 (25.4%) 23 (16.7%) 204 (24.9%)
Visc–Brain 0 2 (2.9%) 9 (3.5%) 13 (3.8%) 5 (3.6%) 27 (3.3%)
Total 76 (100%) 70 (100%) 259 (100%) 346 (100%) 138 (100%) 819 (100%)
Missing 0 0 9 (3.4%) 14 (3.9%) 20 (12.7%) 43 (5.0%)
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from this study). However, a retrospective Swedish study found
that only 1% of patients aged less than 40 presented with
metastases, with this figure increasing successively in each
age cohort (up to 10% for those aged greater than 80).13 In
other retrospective studies of women in the same age
group, the de novo rate was 3.0–3.9%, not dissimilar to what is
reported here.15–17
With regard to the identification of de novo disease, at the time
of recruitment, further preoperative imaging would only have
been performed if the patient had symptoms suggestive of
metastatic disease, or possibly because of clinically positive axillary
nodes or a large primary tumour. The 2009 National Institute of
Clinical Excellence guidelines advised that patients with early
breast cancer should only undergo staging for metastatic disease
in the presence of symptoms.18 CT would not have routinely been
used in all centres; screening for occult metastases may instead
have involved chest radiographs, liver ultrasound and bone
scintigraphy.19 Therefore, women diagnosed with de novo disease
at the time of the POSH study are more likely to have had adverse
tumour features clinically or concerning symptoms. Given that we
have shown younger patients to have a high rate of node
positivity and more advanced T stage, in addition to ER negativity,
it is possible that they were more likely to have baseline imaging.
At the present time, there is no difference in recommended
staging or follow-up for younger patients.11 One retrospective
study found that a baseline PET/CT scan upgraded 15% of young,
asymptomatic patients with early-stage breast cancer to stage
IV.20 Given the better survival for de novo patients here, compared
with those who relapsed within 24 months, and the more adverse
biology in young patients, age should be incorporated into
clinicians’ decision-making with regard to baseline imaging. A
randomised controlled trial would be required to identify whether
routine imaging for metastatic disease at baseline would improve
survival for young patients.
A third of women who developed metastatic disease (34.1%)
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Fig. 1 Kaplan-Meier plots of overall survival. a OS for dnMBC vs. early 12, reference category: dnMBC. b OS for dnMBC vs. early 24, early 24–
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Brain metastases at any time
Yes 30 (39.5%) 27 (38.6%) 83 (32.0%) 119 (34.2%) 34 (24.3%) 266 (32.3%)
No 46 (60.5%) 43 (61.4%) 176 (68.0%) 229 (65.8%) 106 (75.7%) 557 (67.7%)
Total 76 (100%) 70 (100%) 259 (100%) 348 (100%) 140 (100%) 823 (100%)
Missing 0 0 9 (3.4%) 12 (3.3%) 18 (11.4%) 39 (4.5%)
Bone metastases at any time
Yes 54 (71.1%) 38 (54.3%) 163 (62.9%) 240 (69.0%) 100 (71.4%) 557 (67.7%)
No 22 (28.9%) 32 (45.7%) 96 (37.1%) 108 (31.0%) 40 (28.6%) 266 (32.3%)
Total 76 (100%) 70 (100%) 259 (100%) 348 (100%) 140 (100%) 823 (100%)
Missing 0 0 9 (3.4%) 12 (3.3%) 18 (11.4%) 39 (4.5%)
Visceral metastases at any time
Yes 57 (75.0%) 52 (74.3%) 195 (75.3%) 278 (79.9%) 109 (77.9%) 639 (77.6%)
No 19 (25.0%) 18 (25.7%) 64 (24.7%) 70 (20.1%) 31 (22.1%) 184 (22.4%)
Total 76 (100%) 70 (100%) 259 (100%) 348 (100%) 140 (100%) 823 (100%)
Missing 0 0 9 (3.4%) 12 (3.3%) 18 (11.4%) 39 (4.5%)
aIQR, interquartile range.
bTNBC, triple-negative breast cancer.
cChemotherapy refers to cytotoxic chemotherapy only, not hormone, antibody or other therapy.
dVisc, visceral metastatic disease.
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Fig. 2 Kaplan-Meier plots of post-distant relapse-free survival. a PDRS for dnMBC vs. early 12, reference category: dnMBC. b PDRS for
dnMBC vs. early 24, early 24–60 and early 60+ , reference category: dnMBC. c Time-varying HR for PDRS for dnMBC vs. early12, reference
category: dnMBC.
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significantly worse OS compared with those who presented with
metastatic disease. A review of long-term survivorship with
metastatic disease shows 10-year OS rates of 12.45% (95% CI
5.81–21.76) for dnMBC patients, but only 1.73% (0.55–4.24) for
patients who relapsed within 24 months (Fig. 1b). For PDRS,
outcomes were better for de novo disease compared with all
relapsed groups, including those who relapsed late (after 5 years).
Whether the improved outcomes for dnMBC are due to inherently
more favourable biology or different treatment approaches is
unclear. Adjuvant therapy is likely to drive subclonal diversifica-
tion, resulting in mutations that confer resistance to further
cytotoxic/hormonal treatment. Women with de novo disease may
also have been treated more aggressively, e.g., with local therapy
for oligometastatic disease. It might be assumed that late-
relapsing disease (84.2% of whom are ER-positive) is inherently
indolent, but this study challenges that assumption. Either the
metastatic clones present remain dormant until acquiring
sufficient oncogenic drivers, or the clones are present from
diagnosis, but are suppressed by adjuvant hormone therapy.
Further genomic work to understand the subclonal architecture,
and heterogeneity of primary and metastatic sites, is required, in
order to guide treatment strategies in the era of personalised
medicine.
The de novo cohort had a remarkably high prevalence of HER2-
positive tumours (47.9%). The number of HER2+ cases in this
group may contribute to the improved survival seen with dnMBC,
given previous reports of long-term responses to trastuzumab in a
proportion of patients with HER2+MBC.21 However, not all HER2
+ patients received trastuzumab, reflective of the era during
which POSH was recruited. Trastuzumab was approved for use in
the adjuvant setting in 2005, 3 years after the trial began
recruitment. In general, baseline tumour characteristics were
adverse in the early-relapse group, with the greatest proportion of
T2/3, node-positive and LVI tumours. These features may account
for the worse prognosis in this group. The late-relapse group was
marked by ER positivity (84.2% vs. 41.4% in the early-12 group),
node negativity (31.4% vs. 16.2%) and smaller median tumour size
(25 mm vs. 32 mm).
It has been hypothesised that there is a different pattern of
metastatic spread between patients with primary and secondary
metastatic breast cancer. In fact, the de novo group had the
highest proportion of widespread (bone, visceral and brain)
metastases during their disease course (26.3%), although this may
be reflective of their longer survival and the resultant time to allow
dissemination. In addition, their widespread metastases may have
produced symptoms that resulted in their de novo disease being
detected with imaging at diagnosis. The prevalence of HER2
positivity in this group may also account for this. The late-relapse
group was the least likely to develop brain metastases during the
course of their disease (24.3%); proportions were similar for the
dnMBC and early-12 groups (39.5 and 38.6%, respectively).
However, only one of the dnMBC patients (1.3%) had brain
metastases at diagnosis, compared with 18.6% of the early-12
group. This may reflect clinicians being more likely to perform a
baseline CT brain in patients with recurrent, as opposed to newly
diagnosed, breast cancer. Young age has previously been
Table 2. MVAa for OS and PDRS for dnMBC vs. early 12.
OS PDRS
Covariate HR (95% CI), p value
DENOVO
dnMBC 1 (Ref. category) 1 (Ref. category)
Early 12 3.76 (2.22–6.38), <0.001 5.12 (2.95–8.87), <0.001
Age at diagnosis
(years)
0.97 (0.91–1.03), 0.295 0.97 (0.91–1.03), 0.355
BMI
BMI < 25 1 (Ref. category) 1 (Ref. category)
25 ≤ BMI < 30 1.31 (0.76–2.25), p= 0.333 1.27 (0.74–2.20), p= 0.387
BMI ≥ 30 1.30 (0.75–2.27), p= 0.355 1.21 (0.69–2.12), p= 0.498
Grade
1 1 (Ref. category) 1 (Ref. category)
2 7.78 (0.69–87.14), p= 0.096 7.14 (0.65–78.91), p= 0.109
3 5.47 (0.54–55.22), p= 0.150 5.13 (0.51–51.75), p= 0.165
Max invasive
size (mm)
1.00 (0.99–1.01), p= 0.997 1.00 (0.99–1.01), p= 0.900
N stage
N0 1 (Ref. category) 1 (Ref. category)
N1 2.29 (1.17–4.47), p= 0.015 2.42 (1.23–4.77), p= 0.011
HER2 status
Negative 1 (Ref. category) 1 (Ref. category)
Positive 0.50 (0.31–0.80), p= 0.004 0.48 (0.30–0.78), p= 0.003
aMVA Cox model stratified by ER status and ethnicity due to time-varying
hazards.
Table 3. MVAa for PDRS for dnMBC vs. early 24.
Covariate HR (95% CI), p value
DENOVO (time-varying)
dnMBC 1 (Ref. category)
Early 24 (at 2 years) 2.53 (1.50–4.27), 0.00052
Early 24 (at 5 years) 2.42 (1.39–4.22), 0.0019
Early 24 (at 10 years) 3.88 (1.07–14.07), 0.039
Age at diagnosis (years) 1.01 (0.98–1.05), 0.458
BMI
BMI < 25 1 (Ref. category)
25 ≤BMI < 30 1.14 (0.84–1.53), p= 0.403
BMI ≥ 30 1.19 (0.86–1.65), p= 0.301
Grade
1 1 (Ref. category)
2 1.09 (0.24–4.89), p= 0.912
3 1.03 (0.23–4.51), p= 0.971
Max invasive size (mm) 1.00 (0.997–1.01), p= 0.384
N stage
N0 1 (Ref. category)
N1 1.42 (1.05–1.93), p= 0.024
HER2 status
Negative 1 (Ref. category)
Positive 0.66 (0.51–0.86), p= 0.002
Ethnicity
White/Caucasian 1 (Ref. category)
Black 0.61 (0.34–1.12), p= 0.114
Asian 1.63 (0.74–3.61), p= 0.225
Other 0.43 (0.10–1.77), p= 0.240
ER status (time-varying)
Negative 1 (Ref. category)
Positive (at 2 years) 0.50 (0.38–0.67), p < 0.0001
Positive (at 5 years) 0.79 (0.48–1.29), p= 0.350
Positive (at 10 years) 1.30 (0.52–3.25), p= 0.590
aStpm2 model (Flexible parametric survival model). Time varying for
dnMBC vs. early24 and ER status. However, no stratification of ethnicity
incorporated into this model as non-time-varying.
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associated with an increased risk of brain metastases; the
prevalence in this entire cohort was nearly a third (32.3%).11
Clinicians should be vigilant for central nervous system symptoms
in young women during follow-up for breast cancer. There is no
clear evidence that the sites of distant disease explain the differing
prognosis between relapse categories; it seems more likely that
the underlying biology influences metastatic sites, which deter-
mines whether or not a patient presents with de novo disease.
This cohort is unique not only for its age but also for
completeness of BRCA gene mutation testing. It was notable
therefore that a relatively large proportion of patients with de
novo disease (11.8%) had a BRCA2 mutation, whereas just one
(1.3%) had a BRCA1 mutation. Although the 69.3% ER-positivity
rate in this group may explain this to some extent, the ER
positivity was higher in the early-24–60 and late-relapse groups
with a lower BRCA2 prevalence (5.8% and 6.3%, respectively).
Across the cohort of 862 patients with metastatic disease, the
BRCA2 mutation rate was 5.6%; the rate was 5.0% across the POSH
cohort as a whole (excluding dnMBC patients).22 The reason for
such a large proportion of dnMBC cases having a BRCA2 mutation
is unclear; it is possible that a family history of breast and ovarian
cancer in BRCA2 mutation carriers meant that they were more
vigilant regarding symptoms of metastatic disease. In addition,
57% of the dnMBC cohort had bone metastases at presentation
(in common with 69.3% being ER+ ve, the common phenotype
arising from a BRCA2 mutation); perhaps, bone pain in a young
woman is a red- flag symptom that resulted in early imaging. This
might enrich the dnMBC with BRCA2 mutation carriers. Our results
would suggest that further studies using BRCA germline testing in
young women with dnMBC are warranted.
Primary surgery in patients with de novo metastatic breast
cancer remains a debated issue, with decisions made on a case-
by-case basis. In this study, for patients with dnMBC, there was an
improved survival for those who had surgery (n= 50) vs. those
who did not (n= 26), with a univariable HR of 0.41 (p= <0.001).
This outcome is susceptible to selection bias as locoregional
treatment was presumably more likely to occur if disease was
apparently relatively indolent, less widespread and the patient’s
performance status was good. A randomised prospective trial to
address this issue in the modern era is required.
The groups least likely to receive palliative chemotherapy were
the early-12 and late-relapse groups (71.4% and 70.3%, respec-
tively). In the early-12 group, this may be related to lack of
recovery from toxicity following recent adjuvant/neoadjuvant
chemotherapy, radiotherapy and surgery. Physicians may also
have chosen not to treat refractory disease with further systemic
treatment. Amongst the late-relapse group, 84.2% of whom were
ER-positive, most patients received hormone therapy (61.4%). This
is likely to reflect the burden and distribution of metastatic
disease. It may also be that the late relapses were perceived as
more indolent. They experienced less brain metastases compared
with the dnMBC group (24.3% vs. 39.5%), but a similar proportion
of visceral metastases (77.9% vs. 75.0%). In fact, the poor PDRS of
the late-relapse group compared with dnMBC would indicate that
alternative treatment strategies are needed for this cohort.
The potential limitations of this study include its age. As a result,
there have been changes in systemic options available, although
most patients in this study were treated with anthracycline+ /−
taxane chemotherapy, and approximately half of them received
trastuzumab if HER2+ .12 There is an increasingly proactive
approach to staging investigations, including the use of advanced
imaging, such as positron emission tomography. This may mean
that more patients are now diagnosed with occult metastases at
presentation, affecting the characteristics of the de novo group.
Finally, we cannot rule out a degree of selection bias during POSH
recruitment. However, as detailed previously, POSH participants
recruited from England represented 23% of the available
population during the recruitment period, and comparison with
cancer registry data confirmed that the cohort is representative of
the wider population.22 The strengths of this study include the
large cohort size and complete germline BRCA testing. There are
few missing data (with HER2 status missing in only 5.7% of cases)
and long follow-up, with only a small number of patients lost to
follow-up.
CONCLUSION
This is the first report to describe patterns of metastatic disease in
a large prospective cohort of young-onset breast cancer patients,
with a long follow-up period and complete BRCA germline testing.
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Fig. 3 Kaplan-Meier plot of overall survival by surgical category. OS by surgical type (dnMBC patients only); reference category: no surgery.
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We have shown that women aged 40 or less with de novo
metastatic breast cancer have better survival following the onset
of metastatic disease than those who develop secondary breast
cancer. Despite more favourable baseline tumour characteristics,
patients who developed late-onset metastatic disease had a worse
PDRS than de novo patients, indicating that chemotherapy-
resistant clones and/or perceived poor fitness due to prior
therapies have a significant impact on prognosis. A notable
proportion of women with dnMBC had a germline BRCA2
mutation; this has not previously been highlighted in the
literature.
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